Exisulind

Drug Profile

Exisulind

Alternative Names: Aptosyn; FGN 1™; Prevatac™; Sulindac sulfone

Latest Information Update: 18 Jun 2007

Price : $50

At a glance

  • Originator OSI Pharmaceuticals
  • Class Antineoplastics; Small molecules; Sulfones
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cyclic GMP phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Familial adenomatous polyposis; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 18 Jun 2004 Data from a media release have been added to the Cancer therapeutic trials section
  • 12 May 2004 Phase-III clinical trials in Prostate cancer in Canada (PO)
  • 31 Jul 2003 Cell Pathways has been acquired by, and merged into, OSI Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top